Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBP4 Expression in Alopecia Areata Treated With Barcitinib
NCT06545110Phase 1Active, not recruiting
- Sponsor
- South Valley University
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of baricitinib in alopecia areata (2 arms), sponsored by South Valley University. Primary endpoint: Serum and tissue retinol binding protein 4. Started Sep 2023; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT06545110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545110.